Yield on Cost (YOC): 0.45%
The yield on cost (YOC) is 0.45%.
TECH Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
0.45%
Yield on Cost for TECH
TECH now pays $0.32 per share a year. Measured against the price it actually traded at back then, a long-term holder is earning:
| If you bought | Price then | Yield on cost today |
|---|---|---|
| 10 years ago(2016-06-24) | $27.87 | 1.15% |
| 5 years ago(2021-06-22) | $110.47 | 0.29% |
| 3 years ago(2023-06-23) | $76.62 | 0.42% |
| 1 year ago(2025-06-27) | $51.84 | 0.62% |
| Buying today(at $71.00) | $71.00 | 0.45% |
If you buy today and the dividend keeps growing
Projection: starting from today's 0.45% yield, assuming the dividend keeps compounding at its historical 0.0% rate. Boards set dividends each year, so actual figures will differ.
Today
0.45%
In 3 years
0.45%
In 5 years
0.45%
In 10 years
0.45%
Yield on Cost Calculator
Try your own purchase price, dividend and growth rate for Bio-Techne Corporation (TECH).
Starting Yield
0.45%
Ending YOC
1.16%
Year 15 Dividend
$0.82
Cum. Dividends Recd.
$8.24
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $0.32 | — | 0.45% | $0.00 |
| Year 1 | $0.34 | +6.50% | 0.48% | $0.34 |
| Year 2 | $0.36 | +6.50% | 0.51% | $0.70 |
| Year 3 | $0.39 | +6.50% | 0.54% | $1.09 |
| Year 4 | $0.41 | +6.50% | 0.58% | $1.50 |
| Year 5 | $0.44 | +6.50% | 0.62% | $1.94 |
| Year 6 | $0.47 | +6.50% | 0.66% | $2.41 |
| Year 7 | $0.50 | +6.50% | 0.70% | $2.90 |
| Year 8 | $0.53 | +6.50% | 0.75% | $3.43 |
| Year 9 | $0.56 | +6.50% | 0.79% | $4.00 |
| Year 10 | $0.60 | +6.50% | 0.85% | $4.60 |
| Year 11 | $0.64 | +6.50% | 0.90% | $5.24 |
| Year 12 | $0.68 | +6.50% | 0.96% | $5.92 |
| Year 13 | $0.73 | +6.50% | 1.02% | $6.65 |
| Year 14 | $0.77 | +6.50% | 1.09% | $7.42 |
| Year 15 | $0.82 | +6.50% | 1.16% | $8.24 |
Yield on Cost (YOC) Formula & Definition
Yield on cost is the dividend yield measured against your original purchase price, not today's price. As a company raises its dividend, the yield on what you actually paid keeps rising even when the market yield holds steady.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for Bio-Techne Corporation (TECH)?
- The yield on cost (YOC) for TECH stock is 0.45%.
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman